Brief: Amicus Therapeutics Enters Into Supply And Manufacturing Services Agreement With Wuxi

Amicus Therapeutics

24/04/2023 14:02

April 24 (Reuters) - Amicus Therapeutics Inc  FOLD.O :
    * AMICUS THERAPEUTICS INC - ON APRIL 18, 2023, AMICUS
THERAPEUTICS
ENTERED INTO A SUPPLY AND MANUFACTURING SERVICES AGREEMENT WITH
WUXI
    * AMICUS THERAPEUTICS- DEAL HAS INITIAL TERM OF FIVE YEARS
FROM
EFFECTIVE DATE OF AGREEMENT, FOLLOWED BY SUCCESSIVE TWO-YEAR
AUTOMATIC RENEWAL PERIODS
    * AMICUS THERAPEUTICS- WUXI TO MANUFACTURE, SUPPLY TO
AMICUS,
AMICUS TO PURCHASE FROM WUXI,  API IN ATB200 AND  FINISHED
ENZYME REPLACEMENT DRUG PRODUCT
    * AMICUS THERAPEUTICS INC- WUXI AGREEMENT PERMITS AMICUS TO
OBTAIN
API AND DRUG PRODUCT AT CERTAIN WUXI FACILITIES OUTSIDE OF CHINA
    * AMICUS THERAPEUTICS INC - ALSO AGREED TO RESERVE AN
ADDITIONAL
MANUFACTURING SUITE FROM WUXI TO ENSURE APPROPRIATE CAPACITY TO
MEET ATB200 PROJECTIONS
    * AMICUS-DEAL PROVIDES FOR PRICING OF API & DRUG PRODUCT ON
PER
BATCH & PER VIAL BASIS SUBJECT TO ROLLING 18-MONTH FORECAST &
9-MONTH FORECAST RESPECTIVELY

Source: (https://bit.ly/3LnA2nY)
Further company coverage:  FOLD.O 

 ((Reuters.Briefs@thomsonreuters.com;))